What FDA Interchangeable Biosimilar Designation Requires and Which Products Have Achieved It Under Section 351(k) of the Public Health Service Act, a biosimilar can receive interchangeable designation if it meets biosimilarity criteria and demonstrates, via switching studies, that alternating between the biosimilar and the reference product produces no greater safety or efficacy risk than continued use of the reference product
For patients receiving tirzepatide through mail-order pharmacies, the medication should be refrigerated immediately upon receipt
Sterling JK, Adetunji MO, Guttha S et al (2020) GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension
Clinical trials showed A1c reductions of ~0.8%1.0% with albiglutide, a bit less than other GLP-1 RAs, but still significant
Cycle time values were obtained from a QuandStudio 6 Flex qPCR machine (Thermo Scientific, Leiden, The Netherlands)